Development of applicable thiol-linked antibody–drug conjugates with improved stability and therapeutic index

References

• Alas M, Saghaeidehkordi A, Kaur K. (2021). Peptide–drug conjugates with different linkers for cancer therapy. J Med Chem 64:216–32.
   PubMed Web of Science ®Google Scholar
• Alley SC, Benjamin DR, Jeffrey SC, et al. (2008). Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 19:759–65.
   PubMed Web of Science ®Google Scholar
• Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. (2019). Cleavable linkers in antibody–drug conjugates. Chem Soc Rev 48:4361–74.
   PubMed Web of Science ®Google Scholar
• Basle E, Joubert N, Pucheault M. (2010). Protein chemical modification on endogenous amino acids. Chem Biol 17:213–27.
   PubMed Web of Science ®Google Scholar
• Beck A, Goetsch L, Dumontet C, Corvaïa N. (2017). Strategies and challenges for the next generation of antibody–drug conjugates. Nat Rev Drug Discov 16:315–37.
   PubMed Web of Science ®Google Scholar
• Cao L, Xi Z. (2013). Fast thiol–maleamic methyl ester addition for facile covalent cross-linking of oligonucleotides. Tetrahedron Lett 54:1916–20.
   Web of Science ®Google Scholar
• Christie RJ, Fleming R, Bezabeh B, et al. (2015). Stabilization of cysteine-linked antibody drug conjugates with n-aryl maleimides. J Control Release 220:660–70.
   PubMed Web of Science ®Google Scholar
• Coats S, Williams M, Kebble B, et al. (2019). Antibody–drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin Cancer Res 25:5441–8.
   PubMed Web of Science ®Google Scholar
• Criscitiello C, Morganti S, Curigliano G. (2021). Antibody–drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol 14:20.
   PubMed Web of Science ®Google Scholar
• Donaghy H. (2016). Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody–drug conjugates. MAbs 8:659–71.
   PubMed Web of Science ®Google Scholar
• Dovgan I, Kolodych S, Koniev O, Wagner A. (2016). 2-(Maleimidomethyl)-1,3-dioxanes (MD): a serum-stable self-hydrolysable hydrophilic alternative to classical maleimide conjugation. Sci Rep 6:30835.
   PubMed Web of Science ®Google Scholar
• Drago JZ, Modi S, Chandarlapaty S. (2021). Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat Rev Clin Oncol 18:327–44.
   PubMed Web of Science ®Google Scholar
• Fontaine SD, Reid R, Robinson L, et al. (2015). Long-term stabilization of maleimide–thiol conjugates. Bioconjug Chem 26:145–52.
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. (2003). cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458–65.
   PubMed Web of Science ®Google Scholar
• Henkel M, Rockendorf N, Frey A. (2016). Selective and efficient cysteine conjugation by maleimides in the presence of phosphine reductants. Bioconjug Chem 27:2260–5.
   PubMed Web of Science ®Google Scholar
• Huang W, Wu X, Gao X, et al. (2019). Maleimide–thiol adducts stabilized through stretching. Nat Chem 11:310–9.
   PubMed Web of Science ®Google Scholar
• Jha A, Mukherjee C, Prasad AK, et al. (2010). Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore. Bioorg Med Chem Lett 20:1510–5.
   PubMed Web of Science ®Google Scholar
• Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. (2020). Antibody–drug conjugates: the last decade. Pharmaceuticals 13:245.
   Web of Science ®Google Scholar
• Kamimura A, Murakami N, Yokota K, et al. (2002). Regioselective Michael addition of thiols to tertiary fumaric amide esters. Tetrahedron Lett 43:7521–3.
   Web of Science ®Google Scholar
• Kim Y, Ho SO, Gassman NR, et al. (2008). Efficient site-specific labeling of proteins via cysteines. Bioconjug Chem 19:786–91.
   PubMed Web of Science ®Google Scholar
• Knight P. (1979). Hydrolysis of p-NN′-phenylenebismaleimide and its adducts with cysteine. Implications for cross-linking of proteins. Biochem J 179:191–7.
   PubMed Web of Science ®Google Scholar
• Liu G, Shi G, Sheng H, et al. (2017). Doubly caged linker for and-type fluorogenic construction of protein/antibody bioconjugates and in situ quantification. Angew Chem Int Ed Engl 56:8686–91.
   PubMed Web of Science ®Google Scholar
• Lyon RP, Setter JR, Bovee TD, et al. (2014). Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody–drug conjugates. Nat Biotechnol 32:1059–62.
   PubMed Web of Science ®Google Scholar
• Nadkarni DV, Lee J, Jiang Q, et al. (2021). Impact of drug conjugation and loading on target antigen binding and cytotoxicity in cysteine antibody–drug conjugates. Mol Pharm 18:889–97.
   PubMed Web of Science ®Google Scholar
• Peters C, Brown S. (2015). Antibody–drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep 35:e00225.
   PubMed Web of Science ®Google Scholar
• Pryyma A, Gunasekera S, Lewin J, Perrin DM. (2020). Rapid, high-yielding solid-phase synthesis of cathepsin-B cleavable linkers for targeted cancer therapeutics. Bioconjug Chem 31:2685–90.
   PubMed Web of Science ®Google Scholar
• Ravasco J, Faustino H, Trindade A, Gois PMP. (2019). Bioconjugation with maleimides: a useful tool for chemical biology. Chemistry 25:43–59.
   PubMed Web of Science ®Google Scholar
• Ryan CP, Smith ME, Schumacher FF, et al. (2011). Tunable reagents for multi-functional bioconjugation: reversible or permanent chemical modification of proteins and peptides by control of maleimide hydrolysis. Chem Commun 47:5452–4.
   PubMed Web of Science ®Google Scholar
• Shen BQ, Xu K, Liu L, et al. (2012). Conjugation site modulates the in vivo stability and therapeutic activity of antibody–drug conjugates. Nat Biotechnol 30:184–9.
   PubMed Web of Science ®Google Scholar
• Srinivasarao M, Galliford CV, Low PS. (2015). Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov 14:203–19.
   PubMed Web of Science ®Google Scholar
• Tumey LN, Charati M, He T, et al. (2014). Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy. Bioconjug Chem 25:1871–80.
   PubMed Web of Science ®Google Scholar
• Walsh SJ, Bargh JD, Dannheim FM, et al. (2021). Site-selective modification strategies in antibody–drug conjugates. Chem Soc Rev 50:1305–53.
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan S, Xiao D, et al. (2019). Novel silyl ether-based acid-cleavable antibody–MMAE conjugates with appropriate stability and efficacy. Cancers 11:957.
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan S, Zhong W, et al. (2017). Development and properties of valine–alanine based antibody–drug conjugates with monomethyl auristatin E as the potent payload. Int J Mol Sci 18:1860.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu L, Fan S, et al. (2020). Antibody–drug conjugate using ionized Cys-linker-MMAE as the potent payload shows optimal therapeutic safety. Cancers 12:744.
   PubMed Web of Science ®Google Scholar
• Yi L, Li H, Sun L, et al. (2009). A highly sensitive fluorescence probe for fast thiol-quantification assay of glutathione reductase. Angew Chem Int Ed Engl 48:4034–7.
   PubMed Web of Science ®Google Scholar
• Zhao P, Zhang Y, Li W, et al. (2020). Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B 10:1589–600.
   PubMed Web of Science ®Google Scholar
• Zhu X, Huo S, Xue C, et al. (2020). Current LC–MS-based strategies for characterization and quantification of antibody–drug conjugates. J Pharm Anal 10:209–20.
   PubMed Web of Science ®Google Scholar